Treating seronegative neuromyelitis optica spectrum disorder with inebilizumab: a case report

Front Neurol. 2023 Nov 21:14:1297341. doi: 10.3389/fneur.2023.1297341. eCollection 2023.

Abstract

Background: Neuromyelitis optica spectrum disorder (NMOSD) is a devastating inflammatory disease of the central nervous system that is often severely disabling from the outset. The lack of pathognomonic aquaporin 4 (AQP4) antibodies in seronegative NMOSD not only hinders early diagnosis, but also limits therapeutic options, in contrast to AQP4 antibody-positive NMOSD, where the therapeutic landscape has recently evolved massively.

Case presentation: We report a 56-year-old woman with bilateral optic neuritis and longitudinally extensive myelitis as the index events of a seronegative NMOSD, who was successfully treated with inebilizumab.

Conclusion: Treatment with inebilizumab may be considered in aggressive seronegative NMOSD. Whether broader CD19-directed B cell depletion is more effective than treatment with rituximab remains elusive.

Keywords: AQP4; CD19; NMOSD; case report; inebilizumab; longitudinally extensive transverse myelitis; optic neuritis; seronegative.

Publication types

  • Case Reports

Grants and funding

The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This publication was supported by the Open Access Publication Fund of the University of Wuerzburg.